米非司酮治疗子宫肌瘤的临床疗效观察

The clinical effects of mifepristone in treatment with uterine fibroids

目的探讨米非司酮治疗子宫肌瘤的临床效果。方法选取2010年5月至2012年10月期间收治的75例子宫肌瘤患者,均口服米非司酮治疗,根据给药剂量分为10.0 mg/d剂量组、12.5 mg/d剂量组和25.0 mg/d剂量组,每组25例,疗程为3个月。比较治疗前后3组患者的子宫肌瘤大小、血红蛋白水平和卵泡激素(FSH)、黄体生成素(LH)、雌二醇(E2)以及孕酮等激素指标,同时观察不良反应。结果 3组患者治疗后各观察指标与治疗前相比较,子宫肌瘤体积明显缩小,血红蛋白水平增高,各组患者FSH、LH、E2和孕酮等激素水平下降,差异有统计学意义(P<0.05),但不同剂量组间FSH、LH、E2和孕酮等激素水平差异无统计学意义(P>0.05)。结论米非司酮治疗子宫肌瘤安全、有效。

Objective To investigate the clinical effects of mifepristone in treatment with uterine fibroids.Methods 75 patients with uterine fibroids from May 2010 to October 2012 treated with oral mifepristone were divided into three groups with dose at 10.0 mg /d,12.5 mg /d and 25.0 mg /d,respectively,each group with 25 patients.All of the patients were treated for three months,and the size of uterine tumor,the hemoglobin levels,the follicle stimulating hormone（ FSH）,luteinizing hormone（ LH）,estradiol（ E2）and progesterone（ P） and other hormones indicators of the three groups before and after treatment were compared.The adverse drug reactions were also closely observed.Results After three months＇ treatment,the tumor size was significantly reduced（ P〈 0.05）,the amount of hemoglobin was increased（ P〈 0.05）,and the levels of FSH,LH,E2 and P were decreased（ P〈 0.05）,compared with the indicators before treatment.However,the levels of FSH,LH,E2 and P in the three groups were consistent,indicating no relationship with the dose level（ P〉 0.05）.Conclusion Mifepristone in treatment with uterine fibroids is safe and effective.